Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)

医学 无症状的 危险系数 乳腺癌 置信区间 内科学 阶段(地层学) 比例危险模型 癌症 肿瘤科 雌激素受体 放射科 生物 古生物学
作者
Jessica R Schumacher,Heather B Neuman,Menggang Yu,David J Vanness,Yajuan Si,Elizabeth S Burnside,Kathryn J Ruddy,Ann H Partridge,Deborah Schrag,Stephen B Edge,Ying Zhang,Elizabeth A Jacobs,Jeffrey Havlena,Amanda B Francescatti,David P Winchester,Daniel P McKellar,Patricia A Spears,Benjamin D Kozower,George J Chang,Caprice C Greenberg
出处
期刊:Journal of the National Cancer Institute [Oxford University Press]
标识
DOI:10.1093/jnci/djac131
摘要

Guidelines for follow-up after locoregional breast cancer treatment recommend imaging for distant metastases only in the presence of patient signs and/or symptoms. However, guidelines have not been updated to reflect advances in imaging, systemic therapy, or the understanding of biological subtype. We assessed the association between mode of distant recurrence detection and survival.In this observational study, a stage-stratified random sample of women with stage II-III breast cancer in 2006-2007 and followed through 2016 was selected, including up to 10 women from each of 1217 Commission on Cancer facilities (n = 10 076). The explanatory variable was mode of recurrence detection (asymptomatic imaging vs signs and/or symptoms). The outcome was time from initial cancer diagnosis to death. Registrars abstracted scan type, intent (cancer-related vs not, asymptomatic surveillance vs not), and recurrence. Data were merged with each patient's National Cancer Database record.Surveillance imaging detected 23.3% (284 of 1220) of distant recurrences (76.7%, 936 of 1220 by signs and/or symptoms). Based on propensity-weighted multivariable Cox proportional hazards models, patients with asymptomatic imaging compared with sign and/or symptom detected recurrences had a lower risk of death if estrogen receptor (ER) and progesterone receptor (PR) negative, HER2 negative (triple negative; hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.54 to 0.99), or HER2 positive (HR = 0.51, 95% CI = 0.33 to 0.80). No association was observed for ER- or PR-positive, HER2-negative (HR = 1.14, 95% CI = 0.91 to 1.44) cancers.Recurrence detection by asymptomatic imaging compared with signs and/or symptoms was associated with lower risk of death for triple-negative and HER2-positive, but not ER- or PR-positive, HER2-negative cancers. A randomized trial is warranted to evaluate imaging surveillance for metastases results in these subgroups.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
自觉尔白完成签到,获得积分10
刚刚
1秒前
we完成签到,获得积分10
2秒前
6692067完成签到,获得积分10
2秒前
微小桑应助科研通管家采纳,获得10
2秒前
111完成签到,获得积分10
2秒前
如意幻枫完成签到,获得积分10
3秒前
3秒前
4秒前
东方元语应助科研通管家采纳,获得20
4秒前
aaaaaaaaaaaa应助科研通管家采纳,获得10
4秒前
姽婳发布了新的文献求助10
5秒前
姽婳发布了新的文献求助10
5秒前
姽婳发布了新的文献求助10
5秒前
姽婳发布了新的文献求助80
5秒前
姽婳发布了新的文献求助10
5秒前
四月应助科研通管家采纳,获得20
5秒前
所所应助科研通管家采纳,获得30
5秒前
5秒前
Copyright应助俊秀的傲松采纳,获得10
5秒前
俊秀的钥匙完成签到,获得积分10
5秒前
Star发布了新的文献求助10
6秒前
wangdave完成签到,获得积分10
6秒前
6秒前
6秒前
淡然又菡发布了新的文献求助10
7秒前
陈景勇发布了新的文献求助10
8秒前
毛豆应助科研通管家采纳,获得10
8秒前
8秒前
江野林完成签到 ,获得积分10
9秒前
zhixian完成签到,获得积分10
9秒前
Captain完成签到,获得积分10
10秒前
九千岁发布了新的文献求助30
10秒前
陈均涛发布了新的文献求助10
10秒前
科研小呆瓜完成签到,获得积分10
10秒前
受伤的雁开关注了科研通微信公众号
10秒前
xu发布了新的文献求助10
11秒前
兔BF发布了新的文献求助30
11秒前
11秒前
Copyright应助科研通管家采纳,获得10
11秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Gründe der Seele:Die Wiener Psychatrie im 20.Jahrhundert 1000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
Organic Reactions, Volume 116 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7272137
求助须知:如何正确求助?哪些是违规求助? 8892975
关于积分的说明 18799463
捐赠科研通 6946647
什么是DOI,文献DOI怎么找? 3204601
关于科研通互助平台的介绍 2376857
邀请新用户注册赠送积分活动 2180142